Arkolith/Insider Trading/HILS/Form 4

Milby Randy

Chief Executive Officer, DirectorHillstream BioPharma Inc. (HILS) · full profile →Form 4 · filed Apr 19, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
5 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 18, 2022Option exercise(X)8K$0.31$2K2.9M
Apr 18, 2022Option exercise(X)189K$0.08$15K2.9M
Apr 18, 2022Option exercise(X)8K$0.31$2K2.7M
Apr 18, 2022Option exercise(X)8K$0.31$2K2.7M
Apr 18, 2022Option exercise(X)28K$0.08$2K2.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 18, 2022Option exercise(X)8K—$00
Apr 18, 2022Option exercise(X)8K—$00
Apr 18, 2022Option exercise(X)8K—$00
Apr 18, 2022Option exercise(X)28K—$09K
Apr 18, 2022Option exercise(X)189K—$00

Transaction Codes

X
Exercise of in-the-money derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-010294) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML